1378390-39-6

Basic information

• Product Name: tert-butyl 2-[(2-chlorophenyl)methyl]-3-(2-chlorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate
• Synonyms: tert-butyl 2-[(2-chlorophenyl)methyl]-3-(2-chlorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate
• CAS NO: 1378390-39-6
• Molecular Weight: 496.498
• Mol File: 1378390-39-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: tert-butyl 2-[(2-chlorophenyl)methyl]-3-(2-chlorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-[(2-chlorophenyl)methyl]-3-(2-chlorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate(1378390-39-6)
• EPA Substance Registry System: tert-butyl 2-[(2-chlorophenyl)methyl]-3-(2-chlorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate(1378390-39-6)

Safety Data

• Hazardous Substances Data: 1378390-39-6(Hazardous Substances Data)

Upstream product

• 1663-39-4 tert-Butyl acrylate 
• 1307248-45-8 tert-butyl 2′-chloro-4′,5′-dihydrospiro-[piperidine-4,7′-thieno[2,3-c]pyran]-1-carboxylate 
• 1307381-31-2 2'-chloro-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] 
• 1378390-22-7 tert-butyl 3-(2'-chloro-4',5'-dihydro-1H-spiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-yl)propanoate 
• 611-17-6 1-bromomethyl-2-chlorobenzene 

Downstream Products

• 1378389-67-3 2-(2-chlorophenylmethyl)-3-(2-chlorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)-N,N-dimethylpropanamide 
• 1378389-70-8 2-(2-chlorophenylmethyl)-3-(2-chlorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)-N-methylpropanamide 

Relevant articles and documents

Development of LC-MS/MS-based receptor occupancy tracers and positron emission tomography radioligands for the nociceptin/orphanin FQ (NOP) receptor

Currently, a lack of sufficient tools has limited the understanding of the relationship between neuropsychiatric disorders and the nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor. Herein, we describe the discovery and development of an antagonist NOP receptor occupancy (RO) tracer and a novel positron emission tomography (PET) radioligand suitable to probe the NOP receptor in human clinical studies. A thorough structure-activity relationship (SAR) around the high-affinity 3-(2′-fluoro-4′,5′- dihydrospiro[piperidine-4,7′-thieno[2,3-c]pyran]-1-yl)-2-(2-halobenzyl) -N-alkylpropanamide scaffold identified a series of subnanomolar, highly selective NOP antagonists. Subsequently, these unlabeled NOP ligands were evaluated in vivo by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in rat to determine brain uptake, kinetics and specific binding. (S)-27 was identified as a suitable unlabeled preclinical RO tracer to accurately quantify NOP receptor engagement in rat brain. Three compounds were selected for evaluation in nonhuman primates as PET tracers: (-)-26, (-)-30, and (-)-33. Carbon-11 labeling of (+)-31 yielded [11C]-(S)-30, which exhibited minimal generation of central nervous system (CNS) penetrant radiometabolites, improved brain uptake, and was an excellent PET radioligand in both rat and monkey. Currently [11C]-(S)-30 is being evaluated as a PET radiotracer for the NOP receptor in human subjects.